MRL Ventures Fund

Peter Dudek, Ph.D., is the President and Managing Partner and leads the investment team. He is the most senior decision-maker, supported by Partners Karin Kleinhans and Olga Danilchanka, and Senior Associate Tao Fang. The team’s background combines scientific research, operating, and prior venture investing experience.

MRLV sources investments independently of Merck's internal R&D pipeline. The fund operates behind a stated firewall from the parent pharmaceutical company, and its team reviews external early-stage science globally. MRLV does not require a pre-existing Merck relationship for a company to receive investment.

No. MRLV's defining investment term is that it does not require any product or technology rights as a condition of investment. This is a deliberate structural choice meant to make the fund a more attractive partner for founders and co-investors who might otherwise avoid a strategic corporate VC.

The fund states it can lead or co-lead rounds and deploy up to $25M in cumulative capital per company. This starts from initial investments at the concept or preclinical stage and extends through follow-on financings to key clinical inflection points.

No. MRLV explicitly limits its mandate to therapeutics — including small molecules, biologics, and cell therapies — and stated it does not invest in medical devices, diagnostic platforms, or digital health. For digital health, it points to a separate Merck vehicle, the Global Health Innovation Fund.